Seahorse Bioscience, Inc.

Seahorse Bioscience, Inc. acquires BioProcessors Corp.

Seahorse Bioscience, Inc. acquires BioProcessors Corp.

March 9, 2009

Market Vision, Engineering Know-how, and Smart Plastics Expertise Combine to bring Practical Cell Technologies to the Life Sciences

N. Billerica, MA – March 9, 2009 - Seahorse Bioscience, Inc., manufacturer of instruments and consumables for cell based metabolic assays today announced the acquisition of BioProcessors Corp., manufacturer of systems for optimizing biologic drug manufacturing. The two companies will be integrated and operate under the Seahorse name.

BG Medicine, Inc.

BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University

BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University

March 12, 2009

Biosamples from the Framingham Heart Study will be used to Discover New Blood Tests for Heart Disease

WALTHAM, Mass., March 12 /PRNewswire/ -- BG Medicine, a biotechnology company focused on the discovery and development of novel diagnostic biomarkers, today announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health and Boston University (BU).

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347

Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347

March 16, 2009

First Clinical Demonstration of Concert’s Technology Platform

BG Medicine, Inc.

BG Medicine Inc. launches Galectin-3 Website and Commences Galectin-3 Assay Service for Clinical Research

BG Medicine Inc. launches Galectin-3 Website and Commences Galectin-3 Assay Service for Clinical Research

April 1, 2009

WALTHAM, Mass. – (BUSINESS WIRE) - BG Medicine Inc. (BGM), a developer of novel,biomarker-based diagnostic products, today announced the launch of the Galectin-3 Website (www.galectin-3.com) which will provide an array of research materials associated with galectin-3.

Ensemble Therapeutics Corporation

Ensemble Discovery Initiates Collaboration with Bristol-Myers Squibb to Develop Drugs in Novel Therapeutic Class

Ensemble Discovery Initiates Collaboration with Bristol-Myers Squibb to Develop Drugs in Novel Therapeutic Class

April 15, 2009

Alliance will deploy EnsemblinTM platform to access new therapeutic opportunities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Discovery today announced the initiation of a strategic alliance with Bristol-Myers Squibb Company (NYSE: BMY) to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical targets.

VisEn Medical, Inc.

VisEn Launches Next-Generation FAST (“Fluorescence Activatible Sensor Technology”) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo

VisEn Launches Next-Generation FAST (“Fluorescence Activatible Sensor Technology”) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo

April 20, 2009

MMPSense™ 750 FAST is Presented at AACR 100th Annual Meeting

Acceleron Pharma, Inc.

Acceleron Announces Expansion of Cambridge Facilities by Additional 25% During Formal Unveiling of New Corporate Headquarters and Manufacturing Facility

Acceleron Announces Expansion of Cambridge Facilities by Additional 25% During Formal Unveiling of New Corporate Headquarters and Manufacturing Facility

May 1, 2009

Lt. Governor Murray and other Massachusetts Dignitaries on Hand to Celebrate Rapid Growth of Acceleron Product Pipeline and Plans to Further Increase Workforce

Pervasis Therapeutics, Inc.

Pervasis Therapeutics Granted Orphan Drug Designation for Vascugel®

Pervasis Therapeutics Granted Orphan Drug Designation for Vascugel®

May 5, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active cellular therapies to treat vascular and other serious diseases, today announced that it has received Orphan Drug Designation for Vascugel®, a novel allogeneic cell therapy product that may restore natural repair and regeneration pathways in the vasculature, from the U.S. Food and Drug Administration (FDA).

Resolvyx Pharmaceuticals, Inc.

Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting

Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting

May 7, 2009

RX-10045 Promotes Corneal Epithelial Repair in Model System

Topical Administration of Resolvin Effective in Model of Wet AMD

Helicos BioSciences Corporation

Helicos Demonstrates The Utility of Its Single Molecule Sequencing Platform at Cold Spring Harbor Genome Conference

Helicos Demonstrates The Utility of Its Single Molecule Sequencing Platform at Cold Spring Harbor Genome Conference

May 8, 2009

The Helicos System Produces Better Scientific Results with Less Sequencing Required